Riding high from positive clinical trial results for its oral weight-loss therapy, Structure Therapeutics has filed a public offering that it hopes will raise $476 million
Amgen has moved closer to a second indication for its B cell-depleting therapy Uplizna, acquired as part of its $27.8 billion takeover of Horizon Therapeutics last year, a
A man in Mexico has died in what the World Health Organization (WHO) has said is the first lab-confirmed human infection with the H5N2 strain of bird flu.
Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointin
An initiative set up by the FDA to accelerate the development of therapies for rare disease in the same way that Operation Warp Speed delivered COVID-19 vaccine has chosen
There are already two drugs on the market targeting KRAS mutations, for decades considered an undruggable target, but no shortage of drug candidates hoping to follow them.